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Abstract: 
As the catalyst for the rate-limiting reaction step of de novo DNA synthesis, the 
enzyme ribonucleotide reductase (RNR) stands as an important biochemical hub within 
the cell. During rapid cell growth and DNA damage, an increase in RNR activity is 
observed that corresponds with the increased rate of DNA replication. Furthermore, 
inhibition of RNR in cancerous cells has shown to slow tumor growth, indicating that the 
enzyme is a legitimate target for anti-cancer therapy. While several drugs that function as 
RNR inhibitors have proven effective against certain forms of cancer, chemotherapy that 
targets RNR could always be improved in both efficacy and specificity (i.e. minimization 
of side-effects). Thus, further knowledge related to more effective means for RNR 
inhibition has direct clinical applications and is a topic of great research interest. 
This proj ect ainls to develop and implement a fluorescence-based assay for the 
determination of the dissociation constants-a measure of two molecules' affinity for one 
another in solution-between different forms of RNR from the baker's yeast 
Saccharomyces cerevisiae (wild-type and the E689A mutant) and its natural protein 
inhibitor Smll. The exact structural details of how these two proteins interact-details 
that could provide a valuable framework for the design of novel RNR drugs-are 
currently unknown, although it has been confirmed that Smll binds the large subunit of 
yeast RNR, known as Rnrl. Therefore, the assay will be designed to quantify Rnrl-Smll 
interactions, which will be measured indirectly through changes in the fluorescence 
anisotropy of Smll as the concentration of Rnr I is increased. By comparing the 
differences in Smll 's binding affinity for wild-type Rnrl versus the E689A Rnrl mutant, 
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it is hoped that valuable information will be obtained about which RnrI residues interact 
with Smll and are involved in its binding. 
Background: 
Ribonucleotide reductase (RNR) is an enzyme found in all organisms and is 
responsible for catalyzing the conversion of ribonucleosides-UDP, CDP, GDP, and 
ADP-to 2'-deoxyribonucleoside diphosphates I (2' -deoxy-TDP is synthesized by 
thymidilate synthase2). As such, RNR is responsible for maintaining the proper balance 
of cellular dNTP pools, which must be finely tuned to insure that DNA replication takes 
place in a timely and accurate manner. If dNTP pools are too low, replication rates 
decrease; if too high, mutation rates of vital genes increase. Either way, the ultimate 
result is cell death. Thus, RNR is regulated extensively, both at the transcriptionae and 
allosteric4 levels, as well as through subcellular localization in eukaryotes. 5 Due to 
human RNR's status as a target for effective anti-cancer treatment via drugs such as 
hydroxyurea6,7 and Gemcitabine8, which interfere with RNR activity, there has been 
much interest in the molecular/structural basis of RNR catalysis and inhibition, as well as 
in the structural details of RNR's interactions with these drugs. 9 More recently, 
considerable research has been devoted to the development of peptidomimetic-based 
RNR inhibitors (molecular mimics of short peptides) that bind the enzyme with high 
specificity and affinity.lO,Il,12,13 Generally speaking, novel and increasingly effective 
mechanisms for RNR inhibition are currently highly sought after due to the great 
potential for clinical applications. 
Mechanistically, RNR is unique among enzymes in its utilization of long-range, 
radical-dependent electron transport for catalysis-in fact, it was the first protein radical 
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discovered. I4 However, because the RNR reaction mechanism itself is so highly 
conserved throughout the species, different types of RNR are distinguished on the basis 
upon which they generate their free radical, and are divided accordingly into three main 
classes: I, II, and III. Class I RNR-the type found in eukaryotes-utilizes a diiron 
cofactor to produce a radical on one of the protein's tyrosine residues. I5,I6 The major 
steps of the Class I reaction mechanism, as determined in Escherichia coli RNR, include: 
(1) the generation of a tyrosyl radical (Y122) on the p subunit Rnr2, (2) the transport of 
the electron from Rnr2 to the catalytic subunit Rnr1 via several amino acid intermediates, 
(3) the formation of a catalytic thiyl radical (C439) on Rnr1, and (4) the reduction of the 
nucleoside in the active site (involving the residues C439, C462, C225, and E441) 
through a 3'-keto radical intermediate. I ? 
While E. coli RNR has provided mechanistic insight that is extendable to the 
human enzyme, it has also been shown that S. cerevisiae RNR is a good model for 
obtaining relevant structural information due to its high sequence identity (66%) and 
similarity (83%) with human RNR. The yeast enzyme complex exists as an a2PW hetero­
oligomer in solution, with both a-subunits catalytically active. The a-subunit, or large 
subunit, Rnr1 (888 residues; 99.6 kDa) contains the catalytic site as well as the allosteric, 
effector, and specificity sites essential for proper regulation of substrate specificity. The ~ 
subunit Rnr2 (399 residues; 46.1 kDa), as mentioned above, contains the diiron radical 
essential for initiation of catalysis. Finally, the Wsubunit Rnr4 (345 residues; 40.0 kD), 
which is found in S. ceravisiae but not E. coli, is thought to either provide structural 
support for the complex18,19 or assist in iron binding.20 Recently, the three-dimensional x­
ray crystal structures of S. cerevisiae Rnr1 bound with various substrates and effectors 
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were solved by Xu et al 2006. These structures, in addition to providing a completely 
ordered picture of the catalytic site that was consistent with the previously proposed 
catalytic nlechanism, also revealed another important region of the protein, Loop 2, 
which, by undergoing conformational shifts in an effector-dependent manner, confers 
RNR with the ability to preferentially bind and reduce one particular nucleoside over the 
others.21 
The regulation of RNR in S. cerevisiae, in addition to the previously mentioned 
mechanisms, also involves the inhibitory action of the 12 kD (104 residue) protein 
Smll. 22 While its exact mechanism for RNR inhibition is currently unknown, Smll has 
been shown to bind to the Rnrl subunit in a 1: 1 ratio with a dissociation constant of 0.4 
uM. Also, the presence of Smll in a RNR solution does not affect the Rnr 1 
dimer/monomer equilibrium or Rnr 1-Rnr2 association! dissociation equilibria, suggesting 
the possibility that the Rnr 1 binding site for Smll is distinct from those for Rnr 1 
(dimerization), Rnr2, and Rnr4. Interestingly, while there has not been an Smll gene 
identified in mammals, yeast Smll nevertheless binds to and inhibits mouse Rnrl.23 This 
indicates that the structural details of RnrI-Snl11 interactions-details currently unknown 
due to the lack of a crystal structure of the complex-may be relevant to the development 
of novel human RNR inhibitors, thereby justifying investigation of the yeast Smll-Rnrl 
binding mechanism on the basis of drug design. 
Often, when the three-dimensional X-ray crystal structure of a protein complex is 
lacking (such as is the case with the Smll-Rnrl pair), valuable structural information 
about protein-protein binding can still be obtained via less direct means. One such 
approach involves measuring and comparing the binding affinities, usually expressed as 
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dissociation constants (KJ), of various mutant binding-pairs (in which one or more known 
residues are altered in the protein about which structural data is desired) to the wild-type 
pair. Relative changes in affmity indicate that the altered residue is somehow involved­
directly or indirectly-in the binding of the other protein. Therefore, by analyzing many 
different mutants, a picture can be built--one residue at a time--of the regions within the 
protein likely involved in binding. 
Here, the above approach was applied to the Smll-Rnr 1 binding pair through the 
development and utilization of a fluorescence-based assay for the measurement of 
dissociation constants between Snlll and two forms of Rnrl: wild-type (WT) and the 
E689A mutant. By comparison of the KJ obtained for WT Rnrl and a previously 
published value (15), an effective benchmark would be provided for the assay's accuracy 
and precision. The E689 A Rnr 1 was selected for KJ measurement due to previous 
biochemical data that showed that the ICso value (the concentration of Smll at which half 
of the activity of Rnrl is lost) is lower in the mutant than in the wild-type. If this is the 
case, and if Smll inhibition does in fact rely on direct Rnrl binding, then the E689A­
Rnrl'SmllKJ should be lower than that of the WT (eg: it should bind more tightly to the 
mutant than to the wild type protein). 
The assay was designed to be capable of screening, over short periods of time, 
many different Rnr 1 mutants for Smll affinity changes, and also to provide a measurable 
signal that was highly specific to the actual binding event (Le.-a signal relatively 
impervious to random molecular events). Essentially, the assay involved: (1) the labeling 
of the C14S/S60C Smll double mutant with a small molecule fluorescent probe: thiol­
reactive Alexa C5 Maleimide 350 dye24, (2) the titration of the labeled Smll solution 
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with Rnr 1 (either wild-type or E689 A mutant) with simultaneous measurement of 
changes in fluorescence, and (3) the generation of an Smll-Rnr 1 binding curve from 
which a dissociation constant could be extracted. 
There are several practical reasons that Smll was chosen over Rnr 1 to serve as the 
fluorescent protein. First, because this assay addresses the Smll binding site on Rnrl, not 
vice-versa, the affinity of multiple Rnrl variants (here, Wt and the E689A mutant) for a 
single Smll mutant (here, the C14S/S60C double-mutant) must be analyzed. If Smll is 
labeled, then as long as the desired yield is obtained, only one reaction round is 
necessary. Second, for this assay, a high signal to noise ratio depends on a large change 
in the tumbling rate of the fluorescent protein (see next paragraph through p. 8). Because 
changes in tumbling rate are proportional to changes in molecular mass (as affected by a 
binding event), Smll was also selected as the fluorescent protein because its molecular 
weight (12 kD) is much smaller than that of Rnrl (99.6 kD); upon binding, the effective 
change in MW of the fluorescent protein is thus nearly 1000%. Lastly, the C14S/S60C 
Smll mutant, because it contains a single cysteine residue, was chosen on the basis that 
tagging it with the thiol-reactive Alexa Fluor tag would produce only one conjugation 
state. 
To address the issue of specificity, the measured quantity of the assay was not 
merely scalar fluorescence intensity, but rather fluorescence anisotropy (r). A description 
of the degree to which a solution of fluorescent molecules, upon excitation by plane­
polarized light, fluoresces in a direction parallel to the excitation beam, anisotropy is by 
definition a population event.25,26 It hinges on the fact that the only fluorophores excited 
by plane-polarized light in a solution are those whose dipole nloments-at the instant the 
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beam passes through the solution-are aligned with the plane of the beam. Anisotropy is 
best understood mathematically through the following equation, where it is defined in 
terms of polarized emission intensity (I) that is either parallel (III) or perpendicular (lj..) 
to the polarized excitation beam (17, 18): 
(Eq. 1) r = (III 11)1(1 11+ 2 Ii) 
If anisotropy, in the case of freely tumbling fluorophores in solution, IS 
conceptualized as the degree to which an excitation signal's direction vector is 
"randomized" by the fluorophores' random (Brownian) tumbling, then it becomes 
apparent why relative values of anisotropy for a given solution are proportional to 
relative fluorophore tumbling rates. In fact, anisotropy is related to the tumbling rate 
(specifically, the rotational correlation time, <1» and the lifetime of the fluorophore, 't, 
through the Perrin equation, in which ro is the limiting (maximum theoretical) anisotropy 
(18): 
(Eq. 2) r rol(1 + [TI (/>}) 
Because fluorescence lifetime is a kinetic parameter, its value can be assumed as 
constant for a given fluorophore. Thus, a change in the fluorescence anisotropy of a given 
solution will be directly proportional to the change in the fluorophore' s rotational 
correlation time, which can also be expessed as a function of solution viscosity (1]), 
temperature (T), and fluorophore volume (V) (R equals the ideal gas constant) (18): 
(Eq. 3) (/> = 1] VIRT 
For a protein, volume is proportional to the molecular nlass; therefore, changes in 
protein mass-inherent in any protein-protein binding event-correlate directly to 
changes in that protein's fluorescence anisotropy according to equations 2 and 3. Here, 
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the measurement of changes in a fluorescence-labeled Smll solution's anisotropy upon 
incremental addition (titration) of Rnrl provides binding data in the form of percent 
saturation (% bound or % unbound). This is represented by the following equation, in 
which r is the measured anisotropy at a given titrant (Rnr I) concentration, rF is the 
anisotropy of the solution when it is completely in the unbound state (as is assumed to be 
the case when no Rnrl is present), and rB is the anisotropy of the solution when it is 
completely in the bound state (assumed to be equal to the maximum r observed during an 
Smll/Rnrl titration) (18): 
(Eq. 4) % Bound = (r rF)/(rB rF) 
Of course, if the quantum yield (Q) of the fluorescent probe changes as Smll 
transitions from bound to unbound states, then the measured anisotropy values will be 
weighted in favor of the state with the higher Q (i.e. the higher fluorescence emission 
intensity) and will not serve as an accurate representation of percent saturation. In this 
case, a correction factor must be applied to equation (above) to produce equation (below), 
in which (QslQP) is the ratio of the fluorophore's quantum yields in the bound and 
unbound states. Here, QF is assumed to be equal to the fluorescence emission intensity of 
the Smll solution in the absence of Rnr1, and QB is assumed to be equal to that when the 
maximum amount ofyRnrI has been added (18): 
(Eq. 5) % Bound (r - r.tJ/[(rB - r)(QB/QF) + (r - rF)} 
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Materials and Methods: 
Expression and Purification ofS. cerevisiae Smll S60C Mutant: 
BL21 (DE3) pLysS Escherichia coli cells transfonned with the S60C/C14S Smll 
expression plasmid were cultured overnight at 37 deg. C in 50 mL of Luria Broth in the 
presence of 34 mg/L of Chloramphenicol and 100 nlg/L of Ampicillin. Ten milliliters of 
this culture were then added to each of four 2 L flasks containing 500 mL of Terrific 
Broth (TB) with 34 mg/L Chloramphenicol and 100 mg/L Ampicillin. The cells were 
grown at 37 deg. C to an optical density (OD) of 0.6 AU measured at a wavelength of 
600 nm, induced to express S60C/C14S Smll with the addition of isopropyl-B-D­
thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM, and incubated at 37 
deg. C for 3 hours. They were then harvested by centrifugation at 5,000 x g (all 
centrifugation was perfonned at 4 deg. C.), resuspended in Smll buffer (50mM Tris pH 
7.4, 10% Glycerol, ImM EDTA, ImM PMSF, 5mM DTT, Ix Complete protease 
inhibitor), flash-frozen in liquid nitrogen, and stored at -80 deg. C. 
At each stage of the purification process, the presence of S60C/C 14S Smll was 
confinned by SDS-PAGE (Fig. 1). An Amersham G-75 gel filtration column was 
equilibrated with 150 mL of the following buffer: 50mM Tris pH 7.4, 100 mM KC1, 10% 
Glycerol, ImM EDTA, 5mM DTT. The resuspended Smll cells were lysed by thawing at 
4 deg C, and benzonase (1-3 microliters per sample) was added to degrade cellular DNA. 
Upon loss of viscosity, the lysate was centrifuged at 150,000 x g for 1 hour. The 
supernatant was collected and a 25% w/v ammonium sulfate cut was perfonned at 4 deg. 
C for 1 hour, followed by centrifugation at 12,000 x g for 30 minutes. The resulting 
ammonium sulfate pellet was resuspended in 2.5ml of Smll buffer and spun at top speed 
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in a Fisher Accuspin Micro tabletop centrifuge to precipitate excess ammonium sulfate. 
The supernatant was collected and immediately injected into the equilibrated G-75 
column. S60C/C14S Smll was purified via size exclusion chromatography (Fig. 3). The 
presence of S60C/C14S Sml1 was verified by SDS-PAGE (Fig. 1), and the concentration 
was determined by a Bradford protein assay. DTT and excess salt were removed from the 
purified S60C/C 14S Smll sample via a GE-Amersham PD-10 Desalting Column, and a 
Millipore Centriplus YM -10 centrifuge filter was employed to adjust the S60C Sml1 
concentration to 100 J.tM (1.2 mg/mL). 
Reaction ofS60C Smll with Alexa Fluor C5 Maleimide Fluorophore: 
Immediately following purification and concentration, the C 14S/S60C Sml1 
protein sample was conjugated with Invitrogen Alexa 350 Maleimide dye, according to 
the proprietary protocol27 at roonl temperature (see "Appendix: Alexa Fluor 350 
Maleimide Step-by-Step Conjugation Protocol"). In parallel, a separate control solution 
was prepared composed of buffer plus the same concentration of free Alexa fluor dye. 
These reactions were terminated after 2 hours by the addition of excess glutathione (,..., 5 
mg glutathione per 1 mg Alexa dye), and the C 14S/S60C Sml1 containing sample was 
repurified via size exclusion chromatography as before (Fig. 4). This sample's buffer was 
then exchanged by ultrafiltration, and the presence of the Alexa fluorlS60C Smll 
conjugate (Alexa-Smll) was verified by SDS-PAGE (Fig. 2) and a fluorescence emission 
scan (Fig. 4). The conjugate was then appropriately aliquoted, flash-frozen in liquid 
nitrogen, and stored at -80 deg. C. 
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Expression/Purification ofWi/d-Type and E689A S. cerevisiae Rnr1 : 
Both wild-type yeast Rnr1, which was provided by Sanath Wijerathna, as well as 
the E689A mutant were expressed and purified in the same manner. BL21 (DE3) pLysS 
cells transformed with the respective yeast Rnr 1 expression plasmids were cultured 
overnight at 37 deg. C in 10 mL of TB containing 100 mglL Ampicillin and 34 mglL 
Chloramphenicol. The cells were then grown at 37 deg. C in (4) 2 L flasks, each 
containing 500 mL of the same media. When the OD at 600 nm reached 0.6 AU, the cells 
were chilled for 15 minutes at 4 deg. C, induced with 0.5 mM IPTG, and allowed to 
express yRnr 1 overnight at 15 deg. C. Afterwards, the cells were harvested by 
centrifugation at 5000 x g for 30 min. at 4 deg. C and stored at -80 deg. C. 
The cells were thawed on ice and resuspended in a lysis buffer consisting of 100 
mM KCI, 50 mM HEPES-KCI pH 7.0, 5 mM MgCh, 5% (v/v) glycerol, 5 mM DTT, Ix 
Complete protease inhibitor, and 1 mM PMSF. Following multiple passages through 
French pressure at 12,000 psi, the lysate was centrifuged at 12,000 x g for 30 nlin. A 
1.5% weight/volume streptomycin sulfate cut was then performed at 4 deg. C for 30 min., 
followed by 30 nlin. of centrifugation at 15000 x g. A 29% m/v ammonium sulfate cut 
was carried out on the collected supernatant, followed by centrifugation at 15,000 x g for 
30 min. The supernatant was discarded and the ammonium sulfate pellet was stored at 
-80 deg. C. 
All Rnr I purification steps were performed at 4 deg. C. First, the ammonium 
sulfate pellet was thawed on ice, resuspended in buffer (50 mM HEPES-KCI pH 7.0, 5 
mM DTT, 5 mM MgCI2, 5% (v/v) glycerol, 1 mM PMSF, 1 x Complete protease 
inhibitor tablet), and passed through a GE-Amersham PD-IO desalting column. 
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Additional protease inhibitor was added and the mixture was incubated with Rnr2/Rnr4 
peptide affinity resin for 1 hour. The column was washed, first with 20 mL of buffer, then 
with 30 mL buffer + 0.2 M KCl. Rnr 1 was eluted with 10 mL of Rnr 1 buffer + 1 M KCI, 
concentrated via ultrafiltration, frozen in liquid nitrogen, and stored at -80 deg. C. 
Fluorescence Intensity andAnisotropy Measurements: 
All fluorescence measurements were performed at 25 deg. C on a Perkin Elmer 
LS 55 Fluorescence Spectrometer coupled with Perkin Elmer FL Winlab software 
(Version 4.00.03). First, the Alexa-Smll and Rnr1 samples were thawed on ice and their 
concentrations were verified to 10% precision with a three-point-triplicate Bradford 
protein assay. The concentration of Rnr1 was then adjusted so that the desired titration 
increment (Wt 60 nM; E689A 43.7 nM) had a volume of 1 flL. Next, Alexa-Smll 
was mixed in an omnidirectional quartz fluorescence cuvette with "Rnr1 buffer" 
(mentioned earlier: to a final concentration of 0.50 flM. A fluorescence emission 
intensity scan was performed on the Alexa-Sm11 solution, using the following parameters 
in the 'Scan' program (single-scan mode) of Winlab: Excitation (lambda) 346 nm; 
Emission range = 400-595 nm; Em.lExc. slit width 3 nm; (lambda)/min. = 300. This 
was followed by a time-based intensity emission scan with the following parameters: 
Excitation (lambda) = 346 nm; Emission (lambda) = 440 nm; Em.lExc. slit width 3 nm; 
time = 60 sec. (the fluorescence buffer emission profile was subtracted as background in 
both cases). 
After completion of the emission scan, the "Reads" program was opened in 
Winlab and "Anisotropy" mode was selected. Following the calculation of G-factors, the 
Alexa-Smll solution was titrated with Rnr1 (Wt or E689A) and its fluorescence 
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anisotropy measured in a stepwise fashion with the following parameters: Excitation 
(lambda): 346 nnl; emission wavelength: 440 nm; slit-widths: 3 nm; Integration Time: 30 
sec. When the anisotropy appeared to have leveled off near its nlaximum value, one final 
"saturating" titration increment (containing lOx Rnr 1 relative to the previous titration 
increments) was added and the resulting anisotropy nleasured. Finally, a time based 
intensity emission scan was performed on the saturated Alexa-SmlllRnrl solution (same 
parameters as mentioned earlier for the "Smll- only" solution). This entire titration was 
triplicated for both Wt and E689A yRnrl. Control titrations also followed this protocol, 
and were performed once for both Wt and E689A Rnrl by replacing Alexa-Smll with an 
equimolar amount of Alexa-glutathione (Alexa-GSH) conjugate. 
Data Analysis: 
All fluorescence data (Figs. 5-9) were exported directly from FL Winlab to 
Microsoft Excel. Fluorescence intensity emission scan data were used to not only 
establish the presence of fluorescent Alexa-Smll (Fig. 5), but also to establish the 
quantum yield ratio for Alexa-Smll in its bound and unbound states, QB/QF (Figs. 6-7). 
The Alexa-glutathione "control titration" anisotropy data were treated as background 
noise and were subtracted from the corresponding WT RnrllAlexa-Smll and E689A 
Rnr 11Alexa-Smll measured anisotropy values. The resultant standardized values (Fig. 8) 
were then combined with the respective quantum yield ratios in Equation 5 (see p. 9) to 
obtain values for the "fraction of Smll bound by Rnr 1" and generate binding curves for 
Alexa-Smll-WtRnrl and Alexa-Smll-E689A-RnrI (Fig. 9). Finally, these binding 
values were exported from Excel to the Graphpad Prism data analysis suite in order to 
extract the respective dissociation constants. This was accomplished in "XY Graphs," 
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utilizing the "One-site Binding (Hyperbola)" equation with an initial value for K<i of OA 
~lM and a constraint on maximum binding of less than 1.00. The resulting regressions 
(Fig. 10) and their corresponding statistical data (Table 1) were exported to and formatted 
in Excel. 
ResultslDiscussion: 
Initial fluorescence emission intensity scans confirmed both the presence and 
viability of Alexa-Smll (for the control runs, Alexa-GSH) as a fluorophore. The emission 
intensity for 0.5 JlM Alexa-Smll at 440 nm (2.1 x104 AU) provided a relative quantum 
yield value for Alexa-Smll in the unbound state (Qf). As increasing amounts of yRnrI 
were added to the Alexa-Smll solution, a maximum fluorescence anisotropy value was 
approached, indicating that the Alexa-Sml1 was near saturation (% Bound", 1 00). The 
emission intensity values at 440 nm for 0.5 JlM Alexa-Smll in the presence of 2.34 JlM 
WT Rnr1 and 1.32 JlM E689A yRnrI provided relative quantum yield values for Alexa­
Smll in the bound state (QB): 2.9 x 104 RU and 2.3 x 104 RU, respectively. These values 
combined with QF to calculate quantum yield ratios (QB/QF) for wild-type and E689A 
yRnrl of 1.4 and 1.1, respectively. The fluorescence anisotropy curves (Fig. 8) provide 
clear qualitative indication that the E689A mutant binds C14S/S60C Smll more tightly 
than WT Rnr 1. 
The dissociation constant data calculated in GraphPad Prism for each titration are 
summarized in Table 1. For the WT RnrIlCI4S-S60C Smll pair, the average measured 
K<i equals 0.3 j.tM, 0.09 JlM, a value that falls within the error range of the previously 
published value ofOA j.tM, +1- 0.1 j.tM (15), as well as has a degree of precision similar to 
previously published fluorescence anisotropy data. 28,29,30 This result provides strong 
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indication that the assay described here is indeed a legitimate method for quantification 
ofRnrllSmll binding. For the E689A RnrllC14S-S60C Smll pair, the average measured 
KJ of 0.1 J..lM, +/- 0.04 J..lM, provides evidence that Smll binds this mutant more tightly 
than wild-type, an observation that is in agreement with previous biochemical data of 
heightened E689A inhibition by Smll. For both Rnr1 variants, the statistical range of the 
individual KJ values was less than 25% of the average value. R2 values ranged from 0.83 
to 0.85 for WT Rnrl/C14S-S60C Smll and from 0.85 to 0.87 for E689A RnrllC14S­
S60C Sml1. 
When considering the application of this fluorescence assay, as described, to other 
Rnr1 mutants for further characterization of the SmlllRnrl binding mechanism, it 
becomes clear that there is room for optimization. As reflected in the standard error for 
the .Ki values obtained, there were factors that significantly limited the assay's precision. 
Most prominently, the Bradford protein assay, which was used to determine the initial 
concentrations of Smll and Rnr1, is only capable of 90% accuracy; the use of a more 
precise method for concentration measurenlent would likely decrease the standard error 
significantly. Other sources of error include: precision limitations of volume 
measurements (pipet calibration, etc.), calibration of the data acquisition setup 
(spectrometer optics, etc.), and the inclusion of a limited number of data points in each 
binding curve (an increase in the number of titration increments from a few dozen to a 
few hundred would provide further refinement). In the future, minimization of these 
variables in this assay-perhaps through the incorporation of automated, high-throughput 
methods--could allow for the measurement of dissociation constant values to two 
significant figures. This would provide the precision necessary for detection of the small 
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changes in affinity from Rnr 1 mutant to mutant that could be crucial to a true 
understanding of what is taking place structurally. 
In conclusion, this fluorescence-based method provides a viable template for 
characterization of the Smll/Rnr1 binding mechanism through the relative binding 
affinities of Rnr 1 mutants. Sm11' s heightened binding of the E689 A Rnr 1 mutant is one 
piece of the "mechanistic puzzle", but many other Rnr1 residues need to be addressed 
before a picture of how these two proteins interact structurally can begin to emerge. 
Figures/Da ta: 
Figure 1: 15% SDS-PAGE Gel ofC14S/S60C Smll Purification. Lanes, from left to right: (1) Bio-Rad Low 
Range SDS-PAGE Molecular Markers, (2) Smll eel/lysate, (3) Smll post-ammonium sulfate cut, (3) Smll 
supernatant post-tabletop centrifugation, (5) Smll after G75 size-exclusion purification (before 
conjugation with Alexa Fluor 350 C5 Maleimide). Disregard lane 4. 
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Figure 2: 15% SDS-PAGE Gel ofAlexa-tagged C14S/S60C Smll and Wt yRnr1. 

Lanes, from left to right: (1) Bio-Rad Low Range SDS-PAGE Molecular Markers, (2,3) disregard, (4) 

C14S/S60C Smll after conjugation with Alexa Fluor 350 C5 Maleimide and second size-exclusion 

purification, (5) Wt yRnr1 after P7-peptide affinity chromatography and concentration. 

Figure 3: Size-exclusion chromatogram ofSmll (thirdpeak to the right) after G75 size-exclusion 
purification (before conjugation with Alexa Fluor 350 C5 Maleimide). 
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Figure 4: Size exclusion chromatogram ofC14S/S60C Smll after conjugation with Alexa Fluor 350 C5 
Maleimide and second size-exclusion purification. 
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FigureS 
Alexa-Smll Fluorescence Emission Profile (Excitation = 346 nm) 
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Figure 6 
TIme-Based Fluorescence Intensity Scan: Alexa-Sml1lWt yRnr1 
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Figure 7 
Time Based Fluorescence Intensity Scan: Alexa-SmI1/E689AyRnr1 
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Figure 8 
standardized FL Anisotropy: Wt yRnrl/Alexa-Smll and E689A yRnrl/Alexa­
Smll 
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Figure 9 
Bin ding Data: Wt yRnrl/C14S-S60C Smll and E689A yRnrl/C14S-S60C Smll 
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Figure 10 
Regression Data for yRnrl/Smll Binding 
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TABLE 1: Regression Statistical Data 
C14S-560C Sml1fIM yRnr1 Regression Analysis Average Kd Range/Avg. Kd C14S-S60C Sml1/E689A yRnr1 Regression Analysis Average Kd Range/Avg. Kd 
Run 1 Run 2 Run 3 	 Run 1 Run 2 Run 3 
Equation: One site binding (hyperbola) 
Best-fit values 
BMAX 1 1 1 1 1 1 1 1 
KD 0.2476 0.33 0.3107 0.2961 0.278284363 0.1134 0.1287 0.1411 0.12773333 0.216858038 
Std. Error 
BMAX 0.06783 0.08469 0.08636 0.07962667 0.07368 0.07278 0.08877 0.07841 
KD 0.0708 0.1012 0.1003 0.09076667 0.03771 0.03951 0.05033 0.04251667 
95%Confidence Intervals 
BMAX 0.8613 to 1.000 0.8268 to 1.000 0.8234 to 1.000 0.8463 to 1.000 0.8482 to 1.000 0.8148 to 1.000 
KD 0.1028 to 0.3923 0.1229 to 0.5370 0.1055 to 0.5159 0.03475 to 0.1921 0.04630 to 0.2111 0.03616 to 0.2461 
Goodness of Fit 
Degrees of Freedom 29 29 29 29 20 20 20 20 
R2 0.8492 0.8433 0.8307 0.84106667 0.8577 0.8744 0.8469 0.85966667 
Absolute Sum of Squares 0.4441 0.4806 0.5416 0.48876667 0.2992 0.2534 0.3383 0.29696667 
Sy.x 0.1 237 0.1287 0.1367 0.1297 0.1223 0.1126 0.1301 0.12166667 
Constraints 
BMAX BMAX< 1.000 BMAX <1.000 BMAX < 1.000 BMAX <1.000 BMAX < 1.000 BMAX <1.000 
KD KD> 0.0 KD > 0.0 KD >0.0 KD> 0.0 KD > 0.0 KD> 0.0 
Data 
Number of Xvalues 31 31 31 31 22 22 22 22 
Number of Yreplicates 1 1 1 1 1 1 1 1 
Total number of values 31 31 31 31 22 22 22 22 
Number of missing values 0 0 0 0 0 0 0 0 
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Appendix: Alexa Fluor Maleimide Step-by-Step Conjugation Protocol 
Note: Care must be taken to protect Alexa jluorophore from light as much as possible 
before and during conjugation. 
1. 	 Immediately prior to use, prepare 1-10 mM stock solution ofAlexa Fluor 

Maleimide by dissolving in appopriate volume ofDMSO. 

2. 	 Adjust protein (Smll) concentration to 50-100 JlM in suitable buffer (50mM Tris 
pH 7.4,100 mM KCl, 10% Glycerol, 1mM EDT~ without DTT) at room 
temperature. 
3. 	 Place the Smll solution in a Falcon tube and stir. Add Alexa Fluor 
Maleimide/DMSO solution (10 moles Alexa fluor per mole Sml1) dropwise. Cap 
the Falcon tube and allow the reaction to proceed while stirring for 2 hours. 
4. 	 After 2 hours, terminate the reaction by adding an excess amount of glutathione. 
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